Key result
Higher CERT2 score linked to ~71% greater CV death risk and lowered by statins and PCSK9i.
Why the study?
The study aimed to investigate the prognostic value of the CERT2 ceramide-phospholipid risk score and its response to lipid-lowering treatments in patients with symptomatic or suspected coronary heart disease.
Does the CERT2 risk score predict cardiovascular events, and do lipid-lowering therapies reduce this score in patients with suspected or symptomatic coronary heart disease?
Cohort (n=1,088)
Does the CERT2 risk score predict cardiovascular events, and do lipid-lowering therapies reduce this score in patients with suspected or symptomatic coronary heart disease?
Answers are grounded in this paper and cite their sources.
The CERT2 ceramide-phospholipid risk score is a significant predictor of cardiovascular outcomes in patients with suspected coronary heart disease and is modifiable by lipid-lowering therapies.
The aim of the study was to investigate the prognostic value of previously established ceramide-phospholipid risk score, CERT2, and its response to lipid-lowering treatments in patients with symptomatic or suspected coronary heart disease. Selected ceramides and phospholipids were analyzed with a quantitative liquid chromatography-mass spectrometry-based method from plasma or serum samples obtained from the Angiography and Genes study (ANGES, N = 966), and placebo-controlled trials investigating atorvastatin and simvastatin (N = 44) and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor RG7652 (N = 78). In the ANGES, the adjusted hazard ratios (95% confidence interval) per standard deviation for the CERT2 risk score were 1.71 (1.42-2.08) for cardiovascular disease death, 1.36 (1.13-1.64) for myocardial infarction, 1.40 (1.20-1.63) for heart failure, 1.23 (1.08-1.40) for atrial fibrillation, 1.09 (0.89-1.33) for stroke and 1.52 (1.06-2.18) for venous thromboembolism. The median decrease of the CERT2 risk score was 2 points by statin treatment (p≤0.001) and 3 points by PCSK9 inhibition (p<0.001) on the 0-12 scale. The CERT2 risk score is a significant predictor of cardiovascular outcomes in all-comer patients with symptomatic or suspected coronary heart disease. Treatment with lipid-lowering medication significantly lowers the CERT2 risk score.
No takes yet. Share an insight, caveat, or question.
Hilvo et al. (2026) conducted a cohort in symptomatic or suspected coronary heart disease (n=1,088). CERT2 risk score was evaluated on cardiovascular disease death (HR 1.71, 95% CI 1.42-2.08). The CERT2 risk score was associated with cardiovascular disease death and was lowered by statin and PCSK9 inhibitor treatments.
Synapse has enriched 10 related papers. Consider them for comparative context: